Upstream Bio Inc (UPB): Price/Earnings to Growth Multiple
A stable geopolitical backdrop and the absence of sanctions support the development of Upstream Bio Inc (UPB). The PEG ratio demonstrates value dynamics, where the value of 0.00 expresses the metric level. The business is independent of economic cycles, although it remains sensitive to venture capital. The creation of unique antibodies ensures global reach and high scalability with minimal production costs.
Analytical breakdowns for Upstream Bio Inc (UPB)
- price and consensus price forecast:
- stock exchange capitalization data:
- book value of equity indicators:
- issuer credit burden and liquidity indicators:
- business earnings and investment ratios data:
UPB - Net Income|Future Net Profit Upstream Bio Inc|UPB - Price to Earnings Ratio|Future Price to Earnings Multiple Upstream Pharma|UPB - PEG Multiple|Company Value to EBITDA Upstream Bio Corp|UPB - Operating profit EBITDA|Net earnings per share (EPS TTM) Upstream Bio|UPB - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months upstreambio.com|UPB - Net earnings per share growth this year|Expected earnings per share trend next year Upstream Bio Inc
Summary company analytics:UPB Upstream Bio, Inc.
The PEG ratio compares an asset's market value to its earnings growth rate, where a value below one signals that a business is undervalued relative to its expansion. For Upstream Bio Inc (UPB), which is developing innovative biologics, an analysis of undervaluation via the PEG ratio allows for an assessment of the investment attractiveness of the clinical development stage, determining the fundamental fairness of the current share price.
Competitors of Upstream Bio Inc
Growth-Adjusted Market Cap to Net Income argenx N.V.|Price/Earnings to Growth Ratio BioNTech Group BNTX|ABVX - Price/Earnings to Growth Multiple|ADMA - Price/Earnings to Growth Ratio|protagonist-inc.com (PTGX) - Price/Earnings to Growth Multiple|IMVT (Immunovant) - Price/Earnings to Growth Multiple|Kiniksa Pharmaceuticals, Ltd. (KNSA) - PEG Multiple|Price/Earnings to Growth Ratio Grifols Group|Growth-Adjusted P/E Ratio ADPT (Adaptive Biotechnologies Inc.)|PEG Multiple CLDX|AUPH - Price to Earnings Adjusted for Growth Rate|BioCryst Pharmaceuticals - Price/Earnings to Growth Multiple|PEG Multiple Vera Therapeutics Inc VERA|DNTH - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio PHVS|abcellera.com (ABCL) - Price/Earnings to Growth Ratio|TRML - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple PGEN|PHAR (Pharming Group NV) - Company Value to Earnings Growth Ratio|Price/Earnings to Growth Ratio Nektar (NKTR)|ZBIO (Zenas Corp) - Growth-Adjusted Payback Ratio|PEG Multiple IMNM (Immunome, Inc.)|gossamerbio.com (GOSS) - Price to Earnings Adjusted for Growth Rate|KalVista Pharmaceuticals, Inc. - PEG Multiple|SEPN - PEG Multiple|Pieris Pharmaceuticals Inc (PVLA) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple Savara Pharma|Price/Earnings to Growth Multiple RIGL|ANAB: Growth-Adjusted Payback Ratio|PEG Multiple ATXS|Price/Earnings to Growth Ratio ENGN (enGene Holdings Inc)|PEG Multiple RAPT (RAPT Therapeutics, Inc.)|Growth-Adjusted Market Cap to Net Income Aerovate Therapeutics, Inc. (JBIO)|ACRS - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate kyvernatx.com|TLSA (Tiziana Life Sciences Ltd) - Price/Earnings to Growth Multiple|Cabaletta Bio Inc. - Growth-Adjusted Payback Ratio|VTYX (Ventyx Bio) - PEG Multiple|Theratechnologies, Inc (THTX) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Avalo Therapeutics, Inc (AVTX)|eledon.com - Growth-Adjusted P/E Ratio|PEG Multiple AGEN (Agenus Inc.)|CLYM - Price/Earnings to Growth Multiple|ZURA: Price/Earnings to Growth Multiple|ATYR - PEG Multiple|adagene.com (ADAG) - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio IMA (Ikena Oncology)|STTK (Shattuck Labs Inc) - PEG Multiple|Price/Earnings to Growth Ratio EQ|Price/Earnings to Growth Ratio Connect Biopharma (CNTB)|IMUX: Market Cap to Earnings and Growth Ratio|PEG Multiple ATRA (Atara Bio)|Growth-Adjusted Payback Ratio IFRX|X4 Pharmaceuticals, Inc. - PEG Multiple|ACET - PEG Multiple|celularity.com (CELU) - Price/Earnings to Growth Ratio|INmune Bio Corporation - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Barinthus Biotherapeutics|Price/Earnings to Growth Multiple kezarlifesciences.com (KZR)|PEG Multiple SABS|PEG Multiple Akari Therapeutics PLC (AKTX)|Enlivex Therapeutics Ltd. - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio QTTB|GeoVax Labs, Inc. - PEG Multiple|Growth-Adjusted Market Cap to Net Income edesabiotech.com EDSA|iBio (IBIO) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple Carisma Therapeutics Inc.|Price/Earnings to Growth Ratio XTL Biopharmaceuticals, Ltd.|Price/Earnings to Growth Multiple Bolt Bio (BOLT)|Price/Earnings to Growth Multiple HCWB (HCW Biologics Inc.)|PEG Multiple aptevotherapeutics.com (APVO)|Price/Earnings to Growth Ratio AIM ImmunoTech AIM|ADTX: Growth-Adjusted P/E Ratio|GRI Bio Corp - PEG Multiple|Price to Earnings Adjusted for Growth Rate XORTX Corp|HIND (Vyome Holdings Inc) - Price/Earnings to Growth Multiple|revbiosciences.com (REVB) - PEG Multiple|Price/Earnings to Growth Ratio Indaptus Therapeutics, Inc.|Scinai Immunotherapeutics Ltd - Market Cap to Earnings and Growth Ratio|Price/Earnings to Growth Ratio CalciMedica, Inc. (CALI)|Growth-Adjusted Market Cap to Net Income affimed.com|Allakos - Price/Earnings to Growth Multiple|Company Value to Earnings Growth Ratio HOOK (HOOKIPA Pharma, Inc.)|IGMS - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio ITOS (iTeos Therapeutics Inc)|OCEA: PEG Multiple|Price to Earnings Adjusted for Growth Rate TC BioPharm Ltd (TCBP)|THRD (Third Harmonic Bio) - PEG Multiple
